Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell dise...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emole J, Talabi T, Pinilla-Ibarz J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	chronic myelogenous leukemia nilotinib tyrosine kinase inhibitor Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/781e9f4f539e475b828a4cf785a7d206
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:781e9f4f539e475b828a4cf785a7d206
record_format	dspace
spelling	oai:doaj.org-article:781e9f4f539e475b828a4cf785a7d2062021-12-02T05:04:49ZUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib1177-5491https://doaj.org/article/781e9f4f539e475b828a4cf785a7d2062016-02-01T00:00:00Zhttps://www.dovepress.com/update-on-the-management-of-philadelphia-chromosome-positive-chronic-m-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resistance and intolerance to imatinib, there was need for development of second- and third-generation TKIs for the treatment of CML. This review examines the role of nilotinib, an oral second-generation TKI, in the treatment of Philadelphia positive CML. The pharmacology, efficacy, and safety of nilotinib are critically evaluated. Patient-related issues, including tolerance, drug interactions, and quality of life issues are also examined. Keywords: chronic myelogenous leukemia, nilotinib, tyrosine kinase inhibitorEmole JTalabi TPinilla-Ibarz JDove Medical Pressarticlechronic myelogenous leukemia nilotinib tyrosine kinase inhibitorMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 23-31 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myelogenous leukemia nilotinib tyrosine kinase inhibitor Medicine (General) R5-920
spellingShingle	chronic myelogenous leukemia nilotinib tyrosine kinase inhibitor Medicine (General) R5-920 Emole J Talabi T Pinilla-Ibarz J Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
description	Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resistance and intolerance to imatinib, there was need for development of second- and third-generation TKIs for the treatment of CML. This review examines the role of nilotinib, an oral second-generation TKI, in the treatment of Philadelphia positive CML. The pharmacology, efficacy, and safety of nilotinib are critically evaluated. Patient-related issues, including tolerance, drug interactions, and quality of life issues are also examined. Keywords: chronic myelogenous leukemia, nilotinib, tyrosine kinase inhibitor
format	article
author	Emole J Talabi T Pinilla-Ibarz J
author_facet	Emole J Talabi T Pinilla-Ibarz J
author_sort	Emole J
title	Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
title_short	Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
title_full	Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
title_fullStr	Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
title_full_unstemmed	Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
title_sort	update on the management of philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/781e9f4f539e475b828a4cf785a7d206
work_keys_str_mv	AT emolej updateonthemanagementofphiladelphiachromosomepositivechronicmyelogenousleukemiaroleofnilotinib AT talabit updateonthemanagementofphiladelphiachromosomepositivechronicmyelogenousleukemiaroleofnilotinib AT pinillaibarzj updateonthemanagementofphiladelphiachromosomepositivechronicmyelogenousleukemiaroleofnilotinib
_version_	1718400598466887680

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Ejemplares similares